Fluuridine for Injection

After injection, this product is converted into active fluorouridine monophosphate in the body, inhibiting deoxythymidylate synthetase and preventing deoxyuridine methylation from converting to deoxythymidylate, thereby blocking DNA synthesis and inhibiting RNA formation, leading to tumor cell death. This product has hepatotoxic, reproductive toxic and teratogenic effects.

The main ingredients of this product and its chemical name are: The main ingredient of this product is fluuridine, and its chemical name is 5-fluoro-2'-deoxyuridine.

This product is a white loose solid and is hygroscopic.

Applicable to liver cancer, colorectal cancer, esophageal cancer, gastric cancer, <Aclass=bluehref=http://jbk.39.net/keshi/waike/rxwk/4fab3.htmltarget=_b

Each bottle is dissolved with 2.5 ml of water for injection to make a solution containing about 100 mg of fluuridine per 1 ml. When used, it should be appropriately diluted with 5% glucose or 0.9% sodium chloride injection. The effect of administration through hepatic artery catheterization is better for the treatment of liver cancer, 250~500 mg each time, and the dosage for each course of treatment is subject to the doctor's advice. Intravenous drip: Generally 15 mg/kg per body weight, once a day, drip for 2~8 hours, and use it continuously for 5 days. The dose is then halved and once every other day until toxic reactions occur. If adverse reactions occur, the drug should be discontinued, and the drug can be continued after the adverse reactions subside. As long as the drug is still effective for the patient, it should be continued.

The adverse reactions of this product are usually related to complications of local arterial perfusion. Usually manifested as nausea, vomiting, diarrhea, enteritis, stomatitis and localized erythema. Common experimental abnormalities are: anemia, leukopenia, alkaline phosphatase, increased serum bilirubin and lactate dehydrogenase, most of which return to normal after continued medication or reduction or discontinuation of medication. Other adverse reactions are: Gastrointestinal: duodenal ulcer, duodenitis, gastritis, bleeding, gastroenteritis, glossitis, pharyngitis, anorexia, cramps, abdominal pain, and possible hepatobiliary cirrhosis. Skin diseases: hair loss, nonspecific skin toxicity, rash. Cardiovascular: myocardial ischemia. Various clinical reactions: fever, drowsiness, physical discomfort, weakness. Complications caused by local arterial perfusion: aneurysm, arterial ischemia, arterial thrombosis, embolism, fibromyositis, thrombophlebitis, liver necrosis, abscess, catheter infection, catheter bleeding, catheter obstruction, leakage.

1. Patients with a history of severe allergic symptoms to this product are prohibited from using this product. 2. Patients with suppressed myeloid function are prohibited from using this product. 3. Pregnant women are prohibited from using this product. 4. Malnourished patients are prohibited from using this product. 5. Patients with potential severe infections are prohibited from using this product.

Not yet clear.

Keep away from light and store in sealed container.

0.25g

Guangdong Lingnan Pharmaceutical Co., Ltd.

• Founded in:

  1991-04-12

• Address:

  No. 5, Muxi 8th Road, Xilian Town, Wujiang District, Shaoguan City

• Tax NO.:

  91440000190333956C

• Registered Funds:

  11.38 million yuan

• Website:

  Log in to view

• Email:

  Log in to view